At Ipsen, we're inspired by excellence 🌟. This year, five outstanding para-athletes are sharing their insights on what it takes to push beyond limits🏅💪. Discover the testimonies of Margot Boulet and Angélina Lanza 👇✨ Learn More: https://lnkd.in/e6-GTS5h #InspiredByExcellence #ParaAthletes #PushBeyondLimits #Inspiration #SportsForAll #ChampionStories #DisabilityAwareness #InclusionMatters #CelebrateSuccess #IpsenValues
À propos
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com.
- Site web
-
http://www.ipsen.com
Lien externe pour Ipsen
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- 5 001-10 000 employés
- Siège social
- Boulogne Billancourt
- Type
- Société cotée en bourse
- Domaines
- Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins et Primary Care
Lieux
Employés chez Ipsen
Nouvelles
-
Ipsen a republié ceci
Watch Jacqueline's compelling story about her diagnosis with Neuroendocrine Cancer (NET) in our latest video in the Community Compass Campaign in partnership with Ipsen. At 62, her diagnosis sparked crucial reflections on work-life balance. Discover how Jacqueline navigated the challenges of NET symptoms, from heart palpitations to breathlessness, often mistaken for other conditions. Her 7-year journey from symptoms to diagnosis sheds light on the complexity of this disease. Gain insights into the critical role of early detection through a doctor-ordered scan, uncovering a hidden tumour in Jacqueline's abdomen. Education became their power as Jacqueline and Meg dove into understanding the diagnosis, making informed decisions. Meg emphasises the importance of patient education during stressful times. "What Jacq did really well was to educate herself, understand prognosis, and explore treatment options. This empowered open conversations." Join us in promoting awareness, education, and patient support. Watch the video to enhance your understanding of NET and empower patient care. Watch the full video here: https://lnkd.in/gCNfB24V *In partnership with Ipsen, NeuroEndocrine Cancer Australia (NECA) presents the ‘Community Compass Campaign’, a disease awareness initiative empowering patients with neuroendocrine tumours (NETs) to navigate how they live with their condition through the shared experience of other people living with NETs.
-
At Ipsen, we stand with para-athletes, embodying our core values of diversity and inclusion 🤝. This year, we celebrate five para-athletes who inspire us with their success, embodying our passion for diversity and excellence 🏅🌟. Discover the inspiring journey of Valentin Bertrand and Angélina Lanza 👇 Learn more: https://lnkd.in/d2TeYn-6 #DiversityAndInclusion #ParaAthletes #Inspiration #Excellence #SportsForAll #IpsenValues #ChampionStories #DisabilityAwareness #InclusionMatters #CelebrateSuccess
-
Symptoms of the rare cholestatic liver disease #PrimaryBiliaryCholangitis (PBC) are often invisible and poorly understood, yet their impact on quality of life can be significant. Gill’s story is one that continues to drive us at Ipsen to transform the outlook of those living with rare liver disease. Watch Gill’s full story here: https://lnkd.in/gUFU9uey
-
More good news for patients with rare cholestatic liver diseases as the European regulatory advisory body, the Committee for Medicinal Products for Human Use (CHMP), gives Ipsen’s treatments for Primary Biliary Cholangitis and for Alagille Syndrome positive opinions. Following these recommendations for approval a final decision is expected from the European Commission later this year. #PrimaryBiliaryCholangitis #Alagillesyndrome
-
We are celebrating the news that the European regulatory advisory body, the Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for two of our treatments for rare cholestatic liver disease on the same day. A final decision is expected from the European Commission later this year. Learn more: https://lnkd.in/dVtjUjMw
-
-
Ipsen announces partnership with Day One Biopharmaceuticals to bring tovorafenib to children living with pediatric low-grade glioma outside of the U.S.
-
🚀 Strong growth 📈 Progress in our portfolio 🌟 Exciting new assets in the pipeline The first half of the year has been a remarkable journey at Ipsen! We're incredibly proud of our employees' commitment to driving impactful results. Hear what CEO David Loew has to say.
-
Ipsen delivers strong results in the first half of 2024, upgrades its full-year guidance, progresses on launches and announces late-stage deal in oncology. Read more here: https://lnkd.in/efit2t5h
-
-
Ipsen announces partnership with Day One Biopharmaceuticals to bring tovorafenib to children living with pediatric low-grade glioma outside of the U.S. Learn more: https://lnkd.in/dkpWsizj
-
Pages similaires
Parcourir les offres d’emploi
Financement
Dernier round
Capital après introduction en Bourse29 134 597,00 $US